Sepich-Poore, Gregory D. http://orcid.org/0000-0002-3443-3715
McDonald, Daniel
Kopylova, Evguenia
Guccione, Caitlin
Zhu, Qiyun
Austin, George
Carpenter, Carolina
Fraraccio, Serena
Wandro, Stephen
Kosciolek, Tomasz
Janssen, Stefan
Metcalf, Jessica L.
Song, Se Jin
Kanbar, Jad
Miller-Montgomery, Sandrine
Heaton, Robert
Mckay, Rana http://orcid.org/0000-0002-0581-7963
Patel, Sandip Pravin
Swafford, Austin D.
Korem, Tal http://orcid.org/0000-0002-0609-0858
Knight, Rob http://orcid.org/0000-0002-0975-9019
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA255206, U24 CA248454)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | Center for Information Technology (DP1AT010885)
Article History
Received: 23 November 2023
Revised: 3 February 2024
Accepted: 7 February 2024
First Online: 23 February 2024
Change Date: 5 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-024-03018-z
Competing interests
: GDS-P and RK are inventors on a US patent application (PCT/US2019/059647) submitted by The Regents of the University of California and licensed by Micronoma; that application covers methods of diagnosing and treating cancer using multi-domain microbial biomarkers in blood and cancer tissues. GDS-P, RK, and SM-M are founders of and report stock interest in Micronoma. SF and SW are employees of Micronoma. GDS-P has filed several additional US patent applications on cancer bacteriome and mycobiome diagnostics that are owned by The Regents of the University of California and have been licensed by Micronoma. SF, SW, and GDS-P also have filed US patent applications related to cancer microbiome diagnostics that are owned by Micronoma. Additionally, RK is a member of the scientific advisory board for GenCirq, holds an equity interest in GenCirq, and can receive reimbursements for expenses up to US $5,000 per year; he is also an SAB member for DayTwo and BiomeSense, is a consultant for Cybele, is a co-founder of Biota, and owns equity in Biota, Cybele and BiomeSense. D.M. reports being a consultant and owning stock interest in BiomeSense. EK is a founder of Clarity Genomics. Clarity Genomics did not provide funding for this study. No disclosures were reported by the other authors.